Riken Vitamin Co., Ltd. announced a revision to its consolidated earnings guidance for the fiscal year ending March 2026, adjusting net sales to 96,000 million yen (down 4.0% from previous forecast), operating income to 6,200 million yen (down 27.1%), and net income attributable to owners of parent to 6,500 million yen (down 20.7%).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4526","jir_company_name":"Riken Vitamin Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4526-20260212-02.pdf","jir_short_summary":"Riken Vitamin Co., Ltd. announced a revision to its consolidated earnings guidance for the fiscal year ending March 2026, adjusting net sales to 96,000 million yen (down 4.0% from previous forecast), operating income to 6,200 million yen (down 27.1%), and net income attributable to owners of parent to 6,500 million yen (down 20.7%).","jir_summary":"### Overview of Earnings Guidance Revision\nRiken Vitamin Co., Ltd. has revised its consolidated earnings guidance for the fiscal year ending March 2026, lowering net sales to 96,000 million yen (down 4,000 million yen or 4.0% from the previous forecast), operating income to 6,200 million yen (down 2,300 million yen or 27.1%), ordinary income to 7,000 million yen (down 2,000 million yen or 22.2%), and net income attributable to owners of parent to 6,500 million yen (down 1,700 million yen or 20.7%). Net income per share is also expected to decrease to 219.84 yen.\n\n### Reasons for Revision and Future Outlook\nThe primary reasons for the revision are the significant underperformance expected in sales and operating income of overseas businesses due to sluggish consumption in China and intensified price competition in Europe and Southeast Asia. Additionally, a revision in the asset retirement obligation estimate related to asbestos removal costs in the third quarter is expected to substantially reduce operating income in the domestic food business. There is no change to the year-end dividend forecast for the fiscal year ending March 2026.","jir_financial_highlights":"Net Sales: 96,000 million yen (Down 4.0% from previous forecast)\nOperating Income: 6,200 million yen (Down 27.1% from previous forecast)\nOrdinary Income: 7,000 million yen (Down 22.2% from previous forecast)\nNet Income Attributable to Owners of Parent: 6,500 million yen (Down 20.7% from previous forecast)\nNet Income Per Share: 219.84 yen (Decrease from previous forecast)","jir_category":"","jir_hashtags":"#RikenVitaminCoLtd, #EarningsGuidanceRevision, #JapaneseStocks","jir_key_figures":"Net Sales: 96,000 million yen (down 4,000 million yen, 4.0% from previous forecast)\nOperating Income: 6,200 million yen (down 2,300 million yen, 27.1% from previous forecast)\nNet Income Attributable to Owners of Parent: 6,500 million yen (down 1,700 million yen, 20.7% from previous forecast)","jir_meta_title":"Riken Vitamin Downgrades Earnings Guidance to Net Sales of 96,000 Million Yen for Fiscal Year Ending March 2026","jir_meta_description":"Riken Vitamin Co., Ltd. has revised downward its consolidated earnings guidance for the fiscal year ending March 2026, adjusting net sales to 96,000 million yen and operating income to 6,200 million yen, mainly due to sluggish overseas consumption and increased asbestos removal costs.","jir_og_title":"Riken Vitamin Revises Down Earnings Guidance for Fiscal Year Ending March 2026","jir_og_description":"Due to underperformance in overseas operations and increased asbestos removal costs, Riken Vitamin has revised its earnings guidance for the fiscal year ending March 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16690,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-28534","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n